Abstract 1782P
Background
Men with advanced prostate cancer are at risk of upper urinary tract obstruction (UUTO) due to local progression leading to increased morbidity. Primary site radiotherapy (RT) improves overall survival in patients with low volume metastatic hormone sensitive prostate cancer (mHSPC), with limited data available to demonstrate its impact on local progression. Accessible, high quality healthcare systems data (HSD) provides accurate event data beyond standard trial follow up, permitting evaluation of the impact of primary RT on need for UUTO interventions.
Methods
Linked HSD from Hospital Episode Statistics (HES) with follow-up to March 2021 were available for patients randomised 1:1 in England between arms A (standard of care [SOC]) and H (SOC+RT). Radiotherapy was delivered either daily: 55 Gy in 20 fractions over 4 weeks or weekly: 36 Gy in six fractions over 6 weeks. Interventions for UUTO (including percutaneous nephrostomy and or ureteric stent insertion) were identified using a comprehensive coding framework using International Classification of Diseases (ICD 10) diagnosis and Classification of Interventions and Procedures (OPCS 4) codes Multivariate flexible parametric survival models adjusted for randomisation stratification factors were used to estimate the treatment effect of primary RT on the cumulative incidence of UUTO and sub distribution hazard ratios (SDHR).
Results
1791/2061 (88%) were followed up by English hospitals; connected HSD were available for 1724/1791 (96%). After excluding 19 patients who had a UUTO intervention in the 90 days leading to randomisation, model-based 5-year incidence of UUTO requiring intervention was 5% [4; 7%] in patients randomised to SOC, and 3% [2; 4%] in patients randomised to SOC + RT (SDHR 0.568, 95% CI 0.353-0.912; p=0.017). Treatment effects were comparable in high- and low-volume metastasis subgroups.
Conclusions
UUTO interventions are performed in a modest proportion of mHSPC patients. Prostate radiotherapy significantly reduced the use of UUTO interventions. These data support the use of prostate radiotherapy in men with mHSPC at risk of UUTO.
Clinical trial identification
NCT00268476.
Editorial acknowledgement
Legal entity responsible for the study
MRC Clinical Trials Unit and UCL.
Funding
Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.
Disclosure
C. Jones: Financial Interests, Personal, Invited Speaker: Janssen. P. Dutey-Magni, M.R. Sydes: Financial Interests, Institutional, Research Funding: Janssen, Astellas, Novartis, Sanofi, and Clovis. L.R. Murphy, M. Murray, L.C. Brown: Non-Financial Interests, Institutional, Research Funding: Janssen, Astellas, Novartis, Sanofi, and Clovis. N.D. James: Financial Interests, Personal, Advisory Board, Advice around PARP inhibitors: AstraZeneca; Financial Interests, Personal, Advisory Board, Prostate cancer therapies: Janssen, Clovis, Novartis; Financial Interests, Institutional, Advisory Board, Assisted with submissions regarding licensing for abiraterone: Janssen; Financial Interests, Personal, Advisory Board, Docetaxel: Sanofi; Financial Interests, Institutional, Advisory Board, Providing STAMPEDE trial data to facilitate license extensions internationally for docetaxel: Sanofi; Financial Interests, Personal, Advisory Board, Bladder cancer therapy: Merck; Financial Interests, Personal, Advisory Board, Advice around novel hormone therapies for prostate cancer: Bayer; Financial Interests, Personal, Invited Speaker, Lecture tour in Brazil August 2022 - speaking on therapy for advanced prostate cancer: Merck Sharp & Dohme (UK) Limited; Financial Interests, Institutional, Coordinating PI, Funding for STAMPEDE trial: Janssen, Astellas; Financial Interests, Institutional, Coordinating PI, Funding for RADIO trial bladder cancer: AstraZeneca. C. Parker: Other, Personal, Advisory Board: ITM Radiopharma; Financial Interests, Institutional, Advisory Board: AAA. N.W. Clarke: Financial Interests, Personal, Invited Speaker: Janssen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14